

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

**VOLUNTARY ANNOUNCEMENT
SHARE PURCHASE PURSUANT TO THE SECOND H SHARE
AWARD AND TRUST SCHEME**

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the “**Company**”) on a voluntary basis. Reference is made to the announcements of the Company dated June 15, 2023 and July 14, 2023 (the “**Announcements**”), and the circular dated June 28, 2023 (the “**Circular**”), in relation to the adoption of the Second H Share Award and Trust Scheme. Capitalized terms used herein shall have the same meanings as those defined in the Announcements and Circular unless the context requires otherwise.

On January 18, 19 and 22, 2024, the Trustee purchased a total number of 487,000 H Shares (the “**Share Purchase**”) on the market, at a consideration from approximately HK\$21.03 to HK\$26.90 per H Share and a total consideration of approximately HK\$12,054,900 in aggregate, pursuant to the Second H Share Award and Trust Scheme as a long-term equity incentive for employees in the future.

As at the date of this announcement, no Award Shares have been granted to any Selected Participants to the Second H Share Award and Trust Scheme. The Board of Directors or its Delegatee will have full discretion to determine the number of shares to be granted to Selected Participants under the Second H Share Award and Trust Scheme together with vesting criteria and conditions as it deems appropriate.

The Company may make further announcements on the status of the Second H Share Award and Trust Scheme, including the number and price of the H Shares purchased, from time to time.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, the People's Republic of China
January 22, 2024

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive directors.

* *For identification purposes only*